Immunohistochemical markers of uterine myoma recurrence


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Objective: To identify immunohistochemical markers of uterine myoma recurrence. Materials and methods: The study involved 13 patients (Group 1) with newly diagnosed uterine myomas (UM) and 18 patients (Group 2) with recurrent uterine myomas (R UM). All participants underwent laparoscopic reconstructive surgery at the Department of Operative Gynecology of the V.I. Kulakov NMRC for OG&P. Myomatous tissue and nodules of patients who underwent organ-sparing surgery were submitted for pathomorphological and immunohistochemical examination. Analysis included evaluation of the expression of a proliferation marker (Ki-67), vascular endothelial growth factor (VEGF), progesterone (PgR), and estrogen (ER) receptors, p16 protooncogene, and p53 anti-oncogene. Results: VEGF expression was higher in tumor tissue compared to myometrial samples in patients in both groups. The level of Ki-67 in myomatous nodules in Group 2 patients was higher than in Group 1 (p=0.031), which may reflect the proliferative potential of the tumor most susceptible to recurrence. Higher levels of ER and PgR in the myomatous tissue of patients in Group 2 than in Group 1 probably reflect the potential for tumor growth. The expression level of p16 was higher in the myomatous nodules in patients in Group 2 (p=0.027). Apparently, changes in p53 protein expression are not the leading factor in the pathogenesis of uterine myoma, as no statistically significant differences were found in the expression of this protein between the patients of the study groups. Proteins and growth factors identified in tissue samples may be considered potential markers of the disease and its recurrence. Conclusion: High levels of Ki-67, VEGF, p16, ER, and PgR in uterine myoma nodules are pathogenetic factors of myoma recurrence. Morphological evaluation of myometrial tissues and myomatous nodules in patients undergoing surgery for uterine myoma for the first time and for recurrent myoma allows identification of molecular and biological mechanisms of uterine myoma development and recurrence.

Full Text

Restricted Access

About the authors

Narine M. Tonoyan

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: tonnar.13@bk.ru
Obstetrician-Gynecologist at the Department of Operative Gynecology

Irena F. Kozachenko

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Dr. Med. Sci., Senior Researcher at the Department of Operative Gynecology

Aleksandra V. Asaturova

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: a_asaturova@oparina4.ru
Dr. Med. Sci., Head of the lst Pathology Department

Vlada V. Kometova

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: v_kometova@oparina4.ru
PhD, Head of Oncopathology Department

Alina S. Magnaeva

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: alinamagnaeva03@gmail.com
Junior Researcher at the lst Pathology Department

Nadezda S. Tevryukova

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: n.s.tevrukova@yandex.ru
PhD, Senior Researcher at the lst Pathology Department

Vladimir E. Frankevich

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: v_frankevich@oparina4.ru
PhD (Physics and Mathematics), Head of the Department of Systems Biology in Reproduction

Leyla V. Adamyan

Academician V.I. Kulakov National Medical Research Center for Obstetrics, Gynecology and Perinatology, Ministry of Health of Russia

Email: adamyanleila@gmail.com
Dr. Med. Sci., Professor, Academician of RAS, Head of the Department of Operative Gynecology

References

  1. Поротикова И.Е., Адамян Л.В., Гаврилова Т.Ю., Демура Т.А., Козаченко И.Ф., Доброхотова Ю.Э., Асатурова А.В. Особенности хирургического лечения больных миомой матки после ранее перенесенной неэффективной эмболизации маточных артерий и ФУЗ-МРТ абляции. Проблемы репродукции. 2016; 22(3): 45-52. [Porotikova I.E., Adamyan L.V., Gavrilova T.Yu., Demura T.A., Kozachenko I.Ph., Dobrokhotova Iu.E., Asaturova A.V. Surgical treatment of uterine myoma after ineffective UAE and MRgFUS ablation. Russian Journal of Human Reproduction. 2016; 22(3): 45-52. (in Russian)]. https://dx.doi.org/10.17116/repro201622345-52.
  2. Donnez J., Donnez O., Dolmans M.M. With the advent of selective progesterone receptor modulators, what is the place of myoma surgery in current practice? Fertil. Steril. 2014; 102(3): 640-8. https://dx.doi.org/10.1016/j.fertnstert.2014.06.041.
  3. Тоноян Н.М., Козаченко И.Ф., Франкевич В.Е., Чаговец В.В., Адамян Л.В. Рецидивы миомы матки. Современный взгляд на проблемы диагностики, лечения и прогнозирования. Акушерство и гинекология. 2019; 3: 32-8. [Tonoyan N.M., Kozachenko I.F., Frankevich V.E., Chagovets V.V., Adamyan L.V. Recurrences of uterine fibroids. The modern view on the problems of diagnosis, treatment, and prognosis. Obstetrics and Gynecology. 2019; 3: 32-8 (in Russian)]. https://dx.doi.org/10.18565/aig.2019.3.32-38.
  4. Малышкина А.И., Воскресенская Д.Л., Воронин Д.Н., Анциферова Ю.С., Сотникова Н.Ю., Малышкина Д.А. Иммунные механизмы регуляции роста миомы матки. Акушерство и гинекология. 2020; 2: 111-5. [Malyshkina A.I., Voskresenskaya D.L., Voronin D.N., Antsiferova Yu.S., Sotnikova N.Yu., Malyshkina D.A. Immune mechanisms of regulating the growth of uterine leiomyoma. Obstetrics and Gynecology. 2020; 2: 111-5. (in Russian)]. https://dx.doi.org/10.18565/aig.2020.2.111-115.
  5. Караваев Ю.Е., Аскольская С.И., Коган Е.А., Арсланян К.Н., Бурыкина П.Н. Прогностические критерии рецидива лейомиомы матки после реконструктивно-пластических операций. Акушерство и гинекология. 2013; 5: 54-7.
  6. Бурлев В.А. Локальный и системный ангиогенез у больных с миомой матки. Проблемы репродукции. 2007; 1: 26-33.
  7. Munro M.G., Critchley H.O., Fraser I.S.; FIGO Menstrual Disorders Working Group. The FIGO classification of causes of abnormal uterine bleeding in the reproductive years. Fertil. Steril. 2011; 95(7): 2204-8.e3. https://dx.doi.org/10.1016/j.fertnstert.2011.03.079.
  8. Баширов Э.В., Чуприненко Л.М., Крутова В.А. Пролиферативная активность и экспрессия рецепторов стероидных гормонов как предиктор рецидива лейомиомы после органосохраняющих вмешательств. Медицинский вестник Северного Кавказа. 2018; 13: 35-8. [Bashirov E.V., Chuprinenko L.M., Krutova V.A. Molecular biological predictors of myoma growth after organ-saving surgery. Medical News of North Caucasis. 2018; 13: 35-8. (in Russian)]. https://dx.doi.org/10.14300/mnnc.2018.13010.
  9. Мальков П.Г., Франк Г.А., ред. Основы обеспечения качества в гистологической лабораторной технике. Руководство. М.; 2011. 108 с.
  10. Сидорова И.С., Коган Е.А., Унанян А.Л., Киселев В.И., Агеев М.Б. Клиникоморфологические параллели различных вариантов роста миомы матки. Российский вестник акушера-гинеколога. 2019; 19(3): 29-36. [Sidorova I.S., Kogan E.A., Unanian A.L., Kiselev V.I., Ageev M.B. Clinical and morphological correlations for different types of uterine myoma growth. Russian Bulletin of Obstetrician-Gynecologist. 2019; 19(3): 29-36. (in Russian)]. https://dx.doi.org/10.17116/rosakush20191903129.
  11. Шрамко С.В., Бондарев О.И., Коваль Е.Ю., Лоскутова Е.Ю., Подтуркина Т.К., Шишея Е.Ю., Станков А.И., Елдинова О.Г. Биологические маркеры клеточного цикла Ki-67 и Bcl-2 при миоме, аденомиозе и лейомиосаркоме матки. Медицина в Кузбассе. 2019; 18(3): 20-4.
  12. Коган Е.А., Аскольская С.И., Попов Ю.В., Соломахина М.А., Файзуллина Н.М. Лейомиомы матки больших размеров: патогенетические механизмы роста. Клиническая практика. 2016; 7(1): 22-8.
  13. Liao X.H., Li J.Y., Dong X.M., Wang X., Xiang Y., Li H. et al. ERa inhibited myocardin-induced differentiation in uterine fibroids. Exp. Cell Res. 2017; 350(1): 73-82. https://dx.doi.org/10.10167j.yexcr.2016.11.007.
  14. Сидорова И.С., Рыжова О.В., Репин А.Б. Роль апоптоза и клеточной пролиферации в патогенезе гладкомышечных опухолей матки. Российский медико-биологический вестник имени академика И.П. Павлова. 2001; 3-4: 26-31.
  15. Nisolle M., Gillerot S., Casanas-Roux F., Squifflet J., Berliere M., Donnez J. Immunohistochemical study of the proliferation index, oestrogen receptors and progesterone receptors A and B. in leiomyomata and normal myometrium during the menstrual cycle and under gonadotrophin-releasing hormone agonist therapy. Hum. Reprod. 1999; 14(11): 2844-50. https://dx.doi.org/10.1093/humrep/14.11.2844.
  16. Коненков В.И., Королева Е.Г., Орлов Н.Б., Прокофьев В.Ф., Шевченко А.В., Новиков А.М. Сывороточные уровни факторов роста гемопоэза и ангиогенеза (IL-5, IL-7, IL-9, FGF-p, G-CSF, VEGF И. PDGF) у женщин с миомой матки. Медицинская иммунология. 2018; 20(5): 691-8. https://dx.doi.org/10.15789/1563-0625-2018-5-691-698.
  17. Maruo T., Ohara N., Wang J., Matduo H. Sex steroidal regulation of uterine leiomyoma growth and apoptosis. Hum. Reprod. Update. 2004; 10(3): 207-20. https://dx.doi.org/10.1093/humupd/dmh019.
  18. Тюрина А.А., Ящук А.Г., Имельбаева А.Г., Яковлева О.В. Роль прогестерона и тканевых факторов роста в патогенезе миомы матки. Практическая медицина. 2018; 16(6): 124-9. [Tyurina A.A., Yaschuk A.G., Imelbaeva A.G., Yakovleva O.V. The role of progesterone and tissue growth factors in pathogenesis of uterine myomas. Practical Medicine. 2018; 16(6): 124-9. (in Russian)]. https://dx.doi.org/10.32000/2072-1757-2018-16-6-124-129.
  19. Robinson-Rechavi M., Garcia H.E., Laudet V. The nuclear receptor superfamily. J. Cell Sci. 2003; 116(4): 585-6. https://dx.doi.org/10.1242/jcs.00247.
  20. Kirsch D.G., Kastan M.B. Tumor-suppressor p53: implications for tumor development and prognosis. J. Clin. Oncol. 1998; 16(9): 3158-68. https://dx.doi.org/10.1200/JCO.1998.16.9.3158.
  21. Kuhn E., Yemelyanova A., Wang T.L., Kurman R.J. Abstract 5536: TP53 and MED12 mutations in uterine smooth muscle tumors. Canser Res. 2012; 72(8, Suppl.): 5536. https://dx.doi.org/10.1158/1538-7445.AM2012-5536.
  22. Hakverdi S., Demirhan O., Tunc E., Inandiklioglu N., Uslu IN., Gungoren A. et al. Chromosome imbalances and alterations in the p53 gene in uterine myomas from the same family members: familial leiomyomatosis in Turkey. Asian Pac. J. Cancer Prev. 2013; 14(2): 651-8. https://dx.doi.org/10.7314/apjcp.2013.14.2.651.
  23. Atkins K.A., Arronte N., Darus C.J., Rice L.W. The use of p16 in enhancing the histologic classification of uterine smooth muscle tumors. Am. J. Surg. Pathol. 2008; 32(1): 98-102. https://dx.doi.org/10.1097/PAS.0b013e3181574d1e.
  24. Xie J., Ubango J., Ban Y., Chakravarti D., Kim J.J., Wei J.J. Comparative analysis of AKT and the related biomarkers in uterine leiomyomas with MED12, HMGA2, and FH mutations. Genes Chromosomes Cancer. 2018; 57(10): 485-94. https://dx.doi.org/10.1002/gcc.22643.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies